RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.
Share
Why It Matters
An expert still likes Nurix but thinks the stock price might go down a little bit. This could mean the company is doing okay, but maybe not as exciting as before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.